ExecSummary

Webinar E-summary UpTempoSM Antibody: A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic

Speed to clinic is a top priority for the majority of biopharmaceutical companies. Harmonizing technological innovation with platform biomanufacturing development and knowledge can address the time and cost barriers protein biologics face while producing stable, high-expressing antibody-based therapeutics. Catalent’s UpTempoSM Antibody platform process combines the industry-leading GPEx® cell line development technology with streamlined, phase appropriate drug substance development to deliver products from early-stage development through CGMP manufacturing. In addition, UpTempoSM Antibody provides a flexible platform process for multi-chain expression and scalable manufacturing with consistent performance and product quality – all key aspects to deliver biotherapeutics on an expedited timeline for clinical trials.

Learn more about:

How UpTempoSM Antibody addresses key challenges bringing antibody therapeutic programs to clinical trials

What innovative technology and phase appropriate, scalable bioprocessing development are applied from gene to GMP batch release

How to deliver high-expressing, consistent antibody therapeutics on expeditious timelines for clinical studies

Business Email Address*

First Name*

Last Name*

Company*

Title*

Business Phone

Country

State or Province

Buying Horizon*

Asset ID

Asset Type

Asset URL

Download Center - Date Stamp

Download Center - Visit Count

ZZ - Last SFDC Campaign ID

Unique ID

Browser

auxCountry

auxState

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™